Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes

Abstract excerpt

To determine the risk factors and outcomes associated with rising cytomegalovirus (CMV) antigenemia levels during preemptive therapy among stem cell allograft recipients, 119 patients with CMV antigenemia were studied. Patients were prospectively monitored for CMV antigenemia weekly; those with positive findings on antigenemia tests were treated with intravenous ganciclovir (5 mg/kg twice daily for 1 week,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytomegalovirus and herpesvirus research
• Share to Hematopoietic Stem Cell Transplantation
• Share to Herpesvirus Infections and Treatments